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Interferons (IFNs) are mainly produced by immune cells responding to pathogens or malignancies and can be subdivided into two major, functionally distinct classes: Type I and Type II IFNs. Type I IFNs (i.e., IFNα, IFNβ) signal via the IFNα/β receptor, whereas Type II IFN (IFNγ) does so via the IFNγ receptor. Both Type I and Type II IFN receptors are made up of two subunits (i.e., α and β) that-upon engagement-allow for the binding of Janus kinase family members, hence driving the activation of signal transducer and activator of transcription (STAT) family members. The main function of Type I IFNs is to inhibit viral replication. These cytokines are indeed predominantly secreted by plasmacytoid dendritic cells in response to viral nucleic acids. In contrast, IFNγ-which is mainly produced by activated T and natural killer (NK) cells-exerts limited antiviral functions but primarily operates as an immunomodulator and stimulator of monocyte/ macrophage activity. 4 These results were confirmed and extended upon the demonstration that interferon regulatory factor 2, a transcriptional repressor of IFNα signaling, preserves the quiescence and multilineage reconstitution capacities of HSCs. 4 Therefore, Type I IFNs are important modulators of HSC proliferation and differentiation in response to viral infection.
The role of IFNγ in the function of HSCs is also controversially discussed. In several early studies, IFNγ was shown to induce the apoptotic demise or differentiation of murine HSCs in vivo as well as to suppress the growth and colony-forming potential of human CD34 On the other hand, recent studies using well-defined mouse models of physiological infection have challenged these findings and have shed new light on the role of IFNγ during demand-adapted hematopoiesis. During a chronic infection with Mycobacterium avium, IFNγ directly activated quiescent HSCs and induced their proliferation. In addition, HSCs from IFNγ-deficient mice displayed a less exhausted phenotype than HSCs from C57BL/6 mice in secondary transplantation experiments, as indicated by their improved re-population capacities. 7 Furthermore, in Ehrlichia muris-infected mice, IFNγ facilitated infection-induced myelopoiesis to ensure host defenses by supporting the replenishment of myeloid cells. In addition, in a Plasmodium chabaudi-based murine model of malaria, IFNγ promoted the emergence of a myelo-lymphoid progenitor that generated myeloid cells to constrain microbe spread (reviewed in ref. 8) . Altogether, these studies indicate that IFNγ is a potent regulator of HSC function and that the outcome of infection probably depends
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